30,486 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by Bouvel Investment Partners LLC

Bouvel Investment Partners LLC acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,486 shares of the company's stock, valued at approximately $1,029,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the 3rd quarter worth about $30,000. FNY Investment Advisers LLC purchased a new stake in Tempus AI in the 4th quarter worth about $67,000. Vestor Capital LLC bought a new stake in Tempus AI in the third quarter worth about $153,000. Stifel Financial Corp purchased a new position in shares of Tempus AI during the third quarter valued at approximately $218,000. Finally, Sandia Investment Management LP bought a new position in shares of Tempus AI during the second quarter valued at approximately $136,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEM has been the subject of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $56.00 price target on shares of Tempus AI in a research note on Tuesday. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and lifted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Piper Sandler reaffirmed a "neutral" rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a "buy" rating and a $74.00 price objective for the company. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.

Tempus AI Trading Up 1.2 %

NASDAQ TEM traded up $0.40 during trading on Friday, reaching $35.15. 2,434,717 shares of the company's stock traded hands, compared to its average volume of 3,919,255. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company's 50 day simple moving average is $46.03 and its two-hundred day simple moving average is $47.10.

Insider Buying and Selling at Tempus AI

In related news, Director David R. Epstein sold 620 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares in the company, valued at $1,166,248.14. The trade was a 2.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company's stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,300,761 shares of company stock valued at $51,271,197.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.